Alvogen And Pfenex Broaden Teriparatide Collaboration

Alvogen and Pfenex have agreed to expand their existing US collaboration on Pfenex’ PF708 teriparatide candidate to also encompass the EU, certain MENA countries and other international markets.

Hand
Alvogen And Pfenex Have Added The EU, MENA And Other RoW Markets To The Deal • Source: Shutterstock

Alvogen and Pfenex’ collaboration agreement on Pfenex’ PF708 teriparatide candidate has been expanded from the US to also cover the EU, certain Middle East and North Africa (MENA) countries and other international markets. However, the deal excludes China, Hong Kong, Malaysia, Singapore and Thailand.

The initial deal struck last year gave Alvogen exclusive US commercial rights to PF708, a rival to Eli Lilly’s Forteo/Forsteo...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business